Bexagliflozin

Iupac Name：(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

CAS No.: 1118567-05-7

Molecular Weight：464.93586

Modify Date.: 2022-11-24 20:10

Introduction:

Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.target: SGLT2IC50: 5.6 μM (SGLT1)/ 2 nM (SGLT2)1) In normal rats and dogs a saturable urinary glucose excretion was produced with an ED50 of 0.38 and 0.09 mg/kg, respectively.2) EGT1442 significantly prolonged the median survival of SHRSP rats.3) EGT1442 dose-dependently reduced HbA1c and blood glucose concentration without affecting body mass or insulin level.

Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 Diabetes Mellitus.